Nanoscope Therapeutics Inc.
Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company developing gene therapies for retinal diseases.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company focused on developing gene therapies for degenerative retinal diseases that cause vision loss, including retinitis pigmentosa and other inherited retinal conditions. The company is known for its work on optogenetic and gene-agnostic approaches intended to restore vision independent of the specific genetic mutation causing blindness. The supplied evidence for this entry does not contain verifiable information about Nanoscope Therapeutics; the only source provided concerns an unrelated calcium-supplement product launch in Taiwan. As a result, this dossier is limited and should be treated as provisional. Details such as founding year, headquarters, founders, ownership, funding, pipeline specifics, and executive leadership are not documented in the available evidence and are therefore omitted rather than guessed. Readers should consult the company's official communications and regulatory filings for authoritative information on its programs, clinical trial status, and corporate structure.
History
No verifiable history of Nanoscope Therapeutics Inc. is present in the supplied evidence. The single source provided (a Taiwanese news article about nutritionist Kao Min-min's Meta Calcium, Boom Calcium, and calcium gummy products) is unrelated to this company and cannot be used to support any historical claims. A full corporate history is therefore not documented here; it should be compiled from the company's official website, press releases, and clinical trial registries.
Recent events
Nanoscope Therapeutics appoints Troy Short as Senior Vice President, Manufacturing and Supply Chain[2]
Reported:
Nanoscope Therapeutics announced on October 14, 2026 the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In the role, Short will lead Nanoscope's GMP manufacturing, commercial supply, and global distribution strategy as the company advances MOGENRY (sonpiretigene isteparvovec; MCO-010) through regulatory review toward potential approval and launch.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nanoscope-therapeutics-inc · Editorial policy · How profiles are compiled